Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced sialorrhea.

Oliver Freudenreich1

  • 1Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ofreud@massmed.org

Drugs of Today (Barcelona, Spain : 1998)
|August 20, 2005
PubMed
Summary
This summary is machine-generated.

Certain medications can cause significant drooling (sialorrhea), a challenging condition. Treatments often focus on reducing saliva or improving swallowing, with newer options like botulinum injections showing promise for severe cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating Climate Change and Mental Health into Medical Education: A Narrative Review of Interventions and Assessment Tools.

Harvard review of psychiatry·2026
Same author

Clozapine Monitoring: Form Follows Function.

Psychiatric services (Washington, D.C.)·2026
Same author

Implementing Point-of-Care Fingerstick Testing for Clozapine Safety Monitoring in Outpatient Psychiatry: A Convergent Mixed Methods Study.

Community mental health journal·2026
Same author

Evaluating training and competency assessment in public and community psychiatry: a narrative review.

BMC medical education·2025
Same author

Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder: A Multisite, Randomized, Controlled Trial.

The Journal of clinical psychiatry·2025
Same author

Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

The American journal of psychiatry·2025
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Toxicology

Background:

  • Drooling (sialorrhea) is a significant management challenge, often caused by increased saliva production or impaired swallowing.
  • Key drug classes associated with sialorrhea include antipsychotics (e.g., clozapine) and cholinergic agonists used for Alzheimer's disease and myasthenia gravis.
  • Other causes include heavy metal toxicity, acetylcholinesterase inhibitors, and specific drugs like yohimbine.

Purpose of the Study:

  • To review the causes and management strategies for drug-induced drooling.
  • To highlight pharmacological approaches targeting cholinergic and adrenergic systems.
  • To discuss emerging treatments for refractory sialorrhea.

Main Methods:

  • Literature review of drug-induced sialorrhea.

Related Experiment Videos

  • Analysis of pharmacological mechanisms affecting saliva production and swallowing.
  • Evaluation of treatment outcomes for various interventions.

    • Main Results:

    • Antipsychotics and cholinergic agonists are primary medication culprits for drug-induced drooling.
    • Symptomatic treatment often involves reducing saliva flow via anticholinergics or increasing adrenergic tone.
    • Botulinum toxin injections into salivary glands offer a novel approach for difficult-to-treat cases.

    Conclusions:

    • Medication-induced drooling requires careful management, often necessitating a multi-faceted approach.
    • Pharmacological interventions aim to balance saliva production with the patient's swallowing capacity.
    • Advanced treatments like botulinum toxin are valuable for refractory sialorrhea.